title: In vivo requirement for asialo GM1 and Thy1 positive leukocytes for antitumor effect of rIL-2 +/- rIFN-gamma.
abstract: Localized treatment with recombinant human interleukin-2 (rIL-2) +/- recombinant murine interferon-gamma (rIFN-gamma) results in regression of early B16 melanomas in normal C57BL/6 (B6) mice, but not in syngeneic beige mice, which have defective natural killer (NK) cells. Injection of antibodies to asialo GM1 (a-AGM1) or Thy1 abolishes the tymoricidal effects of rIL-1 +/- rIFN-gamma. Thus, cells activated by these cytokines must be either NK-like cells that are AGM1+ Thy1+, or NK-like cells (AGM1+) cooperating with T lymphocytes (Thy1+), since either antibody (a-AGM1 or a-Thy1) independently abrogates the in vivo antitumor effect.
authors.affiliation: Department of Obstetrics and Gynecology, Cornell University Medical College, New York, NY 10021.
authors.forename: S
authors.initials: S
authors.lastname: Silagi
authors.forename: R
authors.initials: R
authors.lastname: Dutkowski
authors.forename: A
authors.initials: A
authors.lastname: Schaefer
mesh_terms: D000818:Animals; D000954:Antigens, Surface / Q000032:analysis*; D005677:G(M1) Ganglioside; D006028:Glycosphingolipids / Q000032:analysis*; D006801:Humans; D007106:Immune Sera; D007371:Interferon-gamma / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007962:Leukocytes / Q000276:immunology*; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D011994:Recombinant Proteins / Q000627:therapeutic use*; D018800:Thy-1 Antigens
chemical_list: D000954:Antigens, Surface; D006028:Glycosphingolipids; D007106:Immune Sera; D007376:Interleukin-2; D011994:Recombinant Proteins; D018800:Thy-1 Antigens; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside; D007371:Interferon-gamma